Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has taken significant strides in international expansion as a strategic lever to boost its business. A central milestone was ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

Hot telehealth stock Hims & Hers Health (NYSE: HIMS) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high. Yet Hims & Hers is still up nearly ...

Telehealth company Hims & Hers Health (NYSE: HIMS) has been great for investors this year by almost any standard; share prices have nearly doubled from a year ago. Yet shareholders aren't feeling ...

Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the health and wellness platform operator skyrocketed more than 670% between ...

Hims & Hers Health also provided a longer-term outlook, laying out expectations for at least $6.5 billion in annual revenue for full-year 2030, and adjusted EBITDA of at least $1.3 billion.